Nonpharmacologic Management of Mixed Dyslipidemia Associated with Diabetes Mellitus and the Metabolic Syndrome: A Review of the Evidence

Neil J. Stone*

*Corresponding author for this work

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Patients with type 2 diabetes mellitus or metabolic syndrome typically exhibit atherogenic mixed dyslipidemia characterized by low levels of high-density lipoprotein cholesterol, elevated triglycerides, and an increase in small, dense low-density lipoprotein particles. Treatment guidelines recognize lifestyle intervention as a first step in the management of dyslipidemia in these patients. The aim of this article is to review evidence to support this approach. To achieve all recommended lipid goals in clinical practice, lifestyle intervention is likely to be adjunctive to pharmacotherapy.

Original languageEnglish (US)
Pages (from-to)14L-18L
JournalAmerican Journal of Cardiology
Volume102
Issue number12 SUPPL.
DOIs
StatePublished - Dec 22 2008

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Nonpharmacologic Management of Mixed Dyslipidemia Associated with Diabetes Mellitus and the Metabolic Syndrome: A Review of the Evidence'. Together they form a unique fingerprint.

  • Cite this